Biohaven Pharmaceutical Holding Company Ltd.'s first commercial product, Nurtec ODT (rimegepant), is off to a solid start as the first and only CGRP inhibitor with US Food and Drug Administration approval for both acute treatment and prevention of migraine. As Biohaven focuses on expanding the drug’s use in both settings, it is also building out a pipeline of drugs to address additional neurological conditions, as investor focus turns to what comes next.
With Biohaven's Nurtec ODT Off And Running, Focus Turns To What Is Next
The oral CGRP inhibitor for migraine generated solid second quarter results as the company expanded to the prevention setting. Several new potential growth drivers are moving through the pipeline.
More from Neurological
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
More from Therapy Areas
• By
The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.